Journal of Functional Biomaterials (Oct 2024)

A Polyurethane Electrospun Membrane Loaded with Bismuth Lipophilic Nanoparticles (BisBAL NPs): Proliferation, Bactericidal, and Antitumor Properties, and Effects on MRSA and Human Breast Cancer Cells

  • Jesús Alejandro Torres-Betancourt,
  • Rene Hernández-Delgadillo,
  • Juan Valerio Cauich-Rodríguez,
  • Diego Adrián Oliva-Rico,
  • Juan Manuel Solis-Soto,
  • Claudia María García-Cuellar,
  • Yesennia Sánchez-Pérez,
  • Nayely Pineda-Aguilar,
  • Samantha Flores-Treviño,
  • Irene Meester,
  • Sergio Eduardo Nakagoshi-Cepeda,
  • Katiushka Arevalo-Niño,
  • María Argelia Akemi Nakagoshi-Cepeda,
  • Claudio Cabral-Romero

DOI
https://doi.org/10.3390/jfb15100309
Journal volume & issue
Vol. 15, no. 10
p. 309

Abstract

Read online

Electrospun membranes (EMs) have a wide range of applications, including use as local delivery systems. In this study, we manufactured a polyurethane Tecoflex™ EM loaded with bismuth-based lipophilic nanoparticles (Tecoflex™ EMs-BisBAL NPs). The physicochemical and mechanical characteristics, along with the antitumor and bactericidal effects, were evaluated using a breast cancer cell line and methicillin-susceptible and resistant Staphylococcus aureus (MRSA). Drug-free Tecoflex™ EMs and Tecoflex™ EMs-BisBAL NPs had similar fiber diameters of 4.65 ± 1.42 µm and 3.95 ± 1.32 µm, respectively. Drug-free Tecoflex™ EMs did not negatively impact a human fibroblast culture, indicating that the vehicle is biocompatible. Tecoflex™ EMs-BisBAL NPs increased 94% more in size than drug-free Tecoflex™ EMs, indicating that the BisBAL NPs enhanced hydration capacity. Tecoflex™ EMs-BisBAL NPs were highly bactericidal against both methicillin-susceptible S. aureus and MRSA clinical isolates, inhibiting their growth by 93.11% and 61.70%, respectively. Additionally, Tecoflex™ EMs-BisBAL NPs decreased the viability of MCF-7 tumor cells by 86% after 24 h exposure and 70.1% within 15 min. Regarding the mechanism of action of Tecoflex™ EMs-BisBAL NPs, it appears to disrupt the tumor cell membrane. In conclusion, Tecoflex™ EMs-BisBAL NPs constitute an innovative low-cost drug delivery system for human breast cancer and postoperative wound infections.

Keywords